NCT02367053View on ClinicalTrials.gov

Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator

PHASE1CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Hypoglycemia
Interventions
DRUG

ZP4207

DRUG

Glucagon

Trial Locations (1)

41460

Profil GmbH, Neuss

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
lead

Zealand Pharma

INDUSTRY